microRNA-100在急性髓细胞白血病中的预后评估价值研究

目的探讨骨髓细胞microRNA-100表达水平对急性髓细胞白血病（AML）患者的预后评估价值。方法选取核型正常AML（CN-AML）患者154例,采用荧光定量RT-PCR法检测骨髓细胞microRNA-100的表达水平,将数值大于等于中位数者归为高表达组,低于中位数者归为低表达组。比较microRNA-100高表达组与低表达组患者的临床特征,包括性别、年龄、FAB分型、Hb、WBC、PLT、原始细胞比例、FLT3-ITD基因突变、NPM1基因突变、化疗后完全缓解情况等。随访48个月,观察并比较两组患者总生存、无事件生存率。结果与高表达组患者比较,低表达组患者的FAB分型M4、M5型比例较高（P＜0.05）,Hb水平较低（P＜0.05）,原始细胞比例较低（P＜0.05）。两组患者性别、年龄、WBC、PLT、FLT3-ITD基因突变、NPM1基因突变、化疗后完全缓解情况比较均无统计学意义（均P＞0.05）。microRNA-100低表达组患者总生存率、无事件生存率均低于高表达组患者（均P＜0.05）。结论microR-NA-100低表达或是AML患者预后差的评估指标。

Value of miR-100 expression in prognosis of patients with cytogenetically normalacute myeloid leukemia

Objective To assess the prognostic value of miR-100 expression in patients with cytogenetically normal acute myeloid leukemia (CN-AML). Methods miR-100 expression was detected by real-time quantitative PCR in bone marrow blasts from 154 patients with CN-AML. Patients with miR-100 expression level higher than the median were defined as high expression group. The age, sex, white cells counts (WBC), hemoglobin, platelet counts (PLT) and therapeutic response were compared be- tween high and low expression groups. The overall survival (OS) and event free survival (EFS) were analyzed after 48 months of follow-up. Results Patients with low miR-100 expression had lower hemoglobin and lower percentage of blasts, but higher fre- quency of FAB M4/5 subtypes. There were no significant differences in age, sex, WBC and PLT, FLT3-ITD and NPM1 gene mu- tations and complete remission rate between high and low expression groups. Patients with low miR-100 expression had poorer OS and EFS than those with high expression. Conclusion miR-100 expression may be used as a prognostic biomarker for patients with CN-AML.